268 related articles for article (PubMed ID: 30528328)
21. The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome.
Emami T; Rezayat SM; Khamesipour A; Madani R; Habibi G; Hojatizade M; Jaafari MR
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):324-333. PubMed ID: 29607698
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
23. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice.
Rostamian M; Bahrami F; Niknam HM
PLoS One; 2018; 13(9):e0204491. PubMed ID: 30248142
[TBL] [Abstract][Full Text] [Related]
25. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with Live Attenuated L. Major and TLR4 Agonist Promotes a Th1 Immune Response and Induces Protection against L. Major Infection in BALB/c Mice.
Noorpisheh Ghadimi S; Farjadian S; Hatam GR; Kalani M; Sarkari B
Iran J Immunol; 2018 Jun; 15(2):74-83. PubMed ID: 29947337
[TBL] [Abstract][Full Text] [Related]
27. Intranasal immunization with Leish-111f induces IFN-gamma production and protects mice from Leishmania major infection.
Sakai SI; Takashima Y; Matsumoto Y; Reed SG; Hayashi Y; Matsumoto Y
Vaccine; 2010 Mar; 28(10):2207-2213. PubMed ID: 20056184
[TBL] [Abstract][Full Text] [Related]
28. Different cytokines are required for induction and maintenance of the Th2 type response in DBA/2 mice resistant to infection with Leishmania major.
Nashed BF; Maekawa Y; Takashima M; Zhang T; Ishii K; Dainichi T; Ishikawa H; Sakai T; Hisaeda H; Himeno K
Microbes Infect; 2000 Oct; 2(12):1435-43. PubMed ID: 11099930
[TBL] [Abstract][Full Text] [Related]
29. Protective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice.
Afonso-Cardoso SR; Rodrigues FH; Gomes MA; Silva AG; Rocha A; Guimaraes AH; Candeloro I; Favoreto S; Ferreira MS; de Souza MA
Korean J Parasitol; 2007 Dec; 45(4):255-66. PubMed ID: 18165707
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
31. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
Daifalla NS; Bayih AG; Gedamu L
Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
[TBL] [Abstract][Full Text] [Related]
32. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation.
Mehravaran A; Jaafari MR; Jalali SA; Khamesipour A; Tafaghodi M; Hojatizade M; Abbasi A; Badiee A
Iran J Immunol; 2015 Dec; 12(4):274-87. PubMed ID: 26714419
[TBL] [Abstract][Full Text] [Related]
33. Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.
Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Dayer MS
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):55-64. PubMed ID: 28779346
[TBL] [Abstract][Full Text] [Related]
34. Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.
Martins VT; Lage DP; Duarte MC; Costa LE; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Tavares CA; Coelho EA
Parasite Immunol; 2016 Feb; 38(2):108-17. PubMed ID: 26756314
[TBL] [Abstract][Full Text] [Related]
35. Immunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swelling.
Hugentobler F; Yam KK; Gillard J; Mahbuba R; Olivier M; Cousineau B
PLoS One; 2012; 7(2):e30945. PubMed ID: 22348031
[TBL] [Abstract][Full Text] [Related]
36. ISCOMs vaccine against experimental leishmaniasis.
Papadopoulou G; Karagouni E; Dotsika E
Vaccine; 1998; 16(9-10):885-92. PubMed ID: 9682333
[TBL] [Abstract][Full Text] [Related]
37. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
38. Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis.
Mehravaran A; Nasab MR; Mirahmadi H; Sharifi I; Alijani E; Nikpoor AR; Akhtari J
Infect Genet Evol; 2019 Jun; 70():27-35. PubMed ID: 30738195
[TBL] [Abstract][Full Text] [Related]
39. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
[TBL] [Abstract][Full Text] [Related]
40. A Laboratory Strain of Leishmania major: Protective Effects on Experimental Leishmaniasis.
Namavari M; Namazi F; Asadi-Manesh R; Hosseini MH; Nazifi S; Asadpour M
Acta Parasitol; 2019 Sep; 64(3):645-651. PubMed ID: 31111360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
